Navigation Links
KBI Biopharma Starts Cell Line Generation Process under Vendor Network Agreement for PER.C6(R)
Date:6/24/2009

DURHAM, N.C., June 24 /PRNewswire/ -- KBI Biopharma, Inc. (KBI) announced today that it has started the process of performing cell line generation with Crucell's PER.C6(R) human cell line platform, pursuant to the Agreement announced by Crucell, The Netherlands, on May 6, 2009. Under that agreement, KBI joins the Vendor Network as a U.S.-based pre-approved cell line generation partner for licensees of the PER.C6(R) cell lines.

KBI is a leading biopharmaceutical contract services company providing fully integrated drug development and biomanufacturing services to pharmaceutical and biotechnology companies globally. KBI, based in Durham, NC, applies cell line generation, extensive protein characterization, manufacturing process development and clinical biomanufacturing capabilities to accelerate and optimize its clients' drug development programs. This comprehensive and integrated suite of services enables clients to bring drugs to market faster and more efficiently. KBI is recognized for its track record in advancing its clients' drug programs by developing scalable, robust processes that result in more stable, active products.

Joseph McMahon, President and CEO of KBI Biopharma notes, "We recognize the significant market interest in and adoption of this technology and are very pleased to now offer cell line generation using the PER.C6(R) cell line." Mr. McMahon added, "Our KBI scientific team has extensive experience producing cell lines in microbial, insect and mammalian systems and are very pleased that Crucell and DSM have recognized our expertise by selecting KBI as a Partner for their Vendor Network."

KBI is now proud to offer the PER.C6(R) technology as part of its extensive capabilities in cell line development.

Other terms of the agreement were not disclosed.

About KBI Biopharma, Inc.

KBI Biopharma, located in Durham, NC, is a leading contract development organization for the biopharmaceutical industry, working with companies across the globe focused on protein-based products. KBI delivers expert and integrated biophysical and biochemical protein characterization, formulation and process development and cGMP manufacturing of recombinant protein Active Pharmaceutical Ingredients (API's). For additional information about KBI Biopharma please visit www.kbibiopharma.com.

PER.C6(R) technology

Crucell's PER.C6(R) technology platform has been developed for the large-scale manufacture of biopharmaceutical products such as recombinant proteins, including monoclonal antibodies. Compared to conventional production technologies, the strengths of PER.C6(R) technology lie in its excellent safety profile, scalability and productivity under serum-free culture conditions. By employing the PER.C6(R) human cell line with a proprietary process technology, a record yield of over 27 grams per liter in the production of IgG antibodies has been achieved.


'/>"/>
SOURCE KBI Biopharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
2. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
3. PDL BioPharma Announces Internal CEO Investigation Found No Credible Evidence of Improper Personal Conduct or Breach of Fiduciary Duty
4. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
5. PDL BioPharma Announces Significant Strategic and Portfolio Changes to Focus on Antibody Discovery and Development
6. XTL Biopharmaceuticals Announces Presentation of Novel Pre-Clinical Inhibitors of Hepatitis C at an Upcoming International Scientific Conference
7. XTL Biopharmaceuticals Initiates Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain
8. Nabi Biopharmaceuticals Announces Sale of Nabi Biologics to Biotest AG
9. Keryx Biopharmaceuticals to Present at Bank of America Investment Conference
10. Morria Biopharmaceuticals Plc Announces Appointment of Dr. Rosemary Mazanet as Interim Chief Executive Officer
11. Keryx Biopharmaceuticals, Inc. Announces Appointment of Michael P. Tarnok to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... ... March 28, 2017 , ... Triumph ... Modular Building Institute (MBI), an international modular trade organization, were awarded First Place, ... for the Pagliuca Life Lab at Harvard University. The awards were presented at ...
(Date:3/28/2017)... SOUTH PLAINFIELD, N.J. and WASHINGTON ... Leading global genomics service provider, GENEWIZ, will launch single-cell sequencing ... Meeting at the Walter E. Washington Convention Center in ... Single-Cell RNA-Seq allows researchers to perform differential gene expression ... Highlights: ...
(Date:3/28/2017)... , March 28, 2017  The National Pharmaceutical ... joined the health policy research organization as its newest ... and Regulatory Affairs ( North America ), ... of Directors. "We,re pleased to have Ipsen ... President Dan Leonard . "We welcome their insights ...
(Date:3/28/2017)... Calif. , March 28, 2017 ... of international life sciences corporation Anpac Bio-Medical ... set a new, international record, processing and reporting ... "Cancer Differentiation Analysis" (CDA) liquid biopsy ... World Nobel Prize Laureate Summit publications, Anpac Bio,s ...
Breaking Biology Technology:
(Date:3/9/2017)... VIEW, Calif. , March 9, 2017 ... 23andMe , the leading personal genetics company, are using ... now provide customers with personalized nutrition plans that consider ... but also genetic markers impacting how their body may ... food decision support platform uses biometrics such as Body ...
(Date:3/2/2017)... Summary This report provides all ... and its partnering interests and activities since 2010. ... The Partnering Deals and Alliance since 2010 report provides ... of the world,s leading life sciences companies. ... ensure inclusion of the most up to date deal ...
(Date:2/28/2017)... News solutions for biometrics, bag drop and ... ... to 16 March, Materna will present its complete end-to-end passenger ... is a real benefit for passengers. To accelerate the whole ... touch point solutions to take passengers through the complete integrated ...
Breaking Biology News(10 mins):